Kunming Pharmaceutical Corp. (KPC) was established in 1951, devoted itself in the development of high technological industrilization of natural drugs. The company involves in the research, manufacture, and promoting natural drugs in the world, strives to be the outstanding representative of technology-oriented and modernized natural drugs supplier in the world and competitive international company.

In December, 2000, the company successfully issued its stock shares in the Shanghai Securities.
In August, 2002, Holley Group successfully merged with KPC, making the company a modern enterprise with nongovernmental, multi-property rights.

After reformation, stock shares issuing and merging into a group, KPC has been successively given the titles of the China Excellent Pharmaceutical Enterprise, The State Key Hi-tech Enterprise,
KPC is the largest comprehensive pharmaceutical enterprise in Yunnan Province, playing an important role in the pharmaceutical industry in Yunnan Province.

KPC has a total staff of more than 2,000, among which technical personnel of different specialties accounts for 45%.
It has Total asset USD 120 million
Net assets USD 62.5 million
Annual output 0.25 billion for injections
3.50 billion for oral formulation

KPC owns 2 pharmaceutical sales subsidiaries, 7 pharmaceutical holding companies, 3 Joint Ventures, 4 manufacturing factories, 1 drug research institute, and 1 pharmaceutical engineering designing institute. The company mainly involves in manufacturing and sales of drug substances extracted from plants, synthetic drugs and medical formulations covering 200 kinds of drugs.

Owing to the advantage of modern research, scale manufacture, Hi-tech products, sales network, natural drug products such as Artemether Series, Nontoginseng Saponins Series, Gastrodin Series and Breviscapine Series have got some market shares home and abroad.

The company also possesses 11 patents such as Combination Anti-malaria Drug of Artemesinin Derivatives and Malaridine, Notoginseng Saponins Soft Capusles and Its Process Procedures, Breviscapine Soft Capusles and Its Process Procedures, Notoginseng Saponins Powder for Injection. KPC has the scale production ability of extracting, refining and synthesizing effective ingredients from plants, synthesizing and semi-synthesizing drug substances; has the scale production ability of manufacturing tablets, capsules, soft capsules, granules, small-volume injection, large-volume injection and powder for injection, etc.

Currently, all of the formulation drugs and Artemether Drug Substance are certificated of Chinese GMP. In addition, Artemether Drug Substance is certificated of GMP of Australian TGA.
The specific anti-malarial drug, Artemether, initialized in China and solely manufactured by KPC is highly praised and recommended by WHO. Many important governmental officials from Africa and South East Asian countries including Patasai, President of Central Africa, Yuangongdan, Vice Premier of Viet Nam, Ben Yang, Standing Vice Premier of the Laos visited KPC and highly praised the efficacy of Artemether.

KPC will enhance communication with the people and governments from different countries, do the realistic work for the control of the harm of the diseases in these countries, contribute to the health and welfare of the people in the countries. At the same time, we also hope to find more partners to co-operate in international trade and explore the international pharmaceutical market together.